Genelux Corporation (GNLX) vs Rani Therapeutics Holdings, Inc. (RANI)

Genelux Corporation and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Genelux Corporation and Rani Therapeutics Holdings, Inc. are of similar size ($110.0M and $107.3M). Genelux Corporation has the higher net margin (0.00% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Genelux Corporation leads on 7 and Rani Therapeutics Holdings, Inc. on 7.

Valuation

Metric GNLX RANI Biotechnology median
P/E n/m n/m 7.88
P/S 9.91 28.17 11.47
P/B 6.92 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 8.37 20.72 10.73
Earnings yield (34.68%) (35.53%) (28.84%)
Free cash flow yield (25.73%) (14.30%) (23.03%)

Profitability

Metric GNLX RANI Biotechnology median
Gross margin (3.42%) 100.00% 65.16%
Operating margin 0.00% (652.78%) 0.00%
Net margin 0.00% (596.97%) 0.00%
Free cash flow margin 0.00% (402.83%) 0.00%
Return on equity (177.93%) (155.24%) (57.72%)
Return on assets (121.80%) (77.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNLX RANI Biotechnology median
Revenue growth (TTM) — 78.73% 5.64%
EPS growth (last fiscal year) 9.47% 57.14% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX RANI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 5.31 4.73
Net debt to EBITDA 0.44 1.33 0.96

Dividend

Metric GNLX RANI Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric GNLX RANI Biotechnology median
Market cap 109.95m 107.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack